Itālija - itāļu - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - dasatinib - dasatinib

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - dasatinibum - compresse rivestite con film - dasatinibum 70 mg, cellulosum microcristallinum, lactosum monohydricum 96.6 mg, carmellosum natricum conexum, hydroxypropylcellulosum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, talcum, glyceroli monopalmitostearas, natrii laurilsulfas, pro compresso obducto corresp. natrium 2.038 mg. - onkologikum, multi-kinase-hemmer - synthetika

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - dasatinibum - compresse rivestite con film - dasatinibum 20 mg, cellulosum microcristallinum, lactosum monohydricum 27.6 mg, carmellosum natricum conexum, hydroxypropylcellulosum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, talcum, glyceroli monopalmitostearas, natrii laurilsulfas, pro compresso obducto corresp. natrium 0.582 mg. - onkologikum, multi-kinase-hemmer - synthetika

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - dasatinibum - compresse rivestite con film - dasatinibum 50 mg, cellulosum microcristallinum, lactosum monohydricum 69 mg, carmellosum natricum conexum, hydroxypropylcellulosum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, talcum, glyceroli monopalmitostearas, natrii laurilsulfas, pro compresso obducto corresp. natrium 1.456 mg. - onkologikum, multi-kinase-hemmer - synthetika

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - dasatinibum - compresse rivestite con film - dasatinibum 80 mg, cellulosum microcristallinum, lactosum monohydricum 110.4 mg, carmellosum natricum conexum, hydroxypropylcellulosum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, talcum, glyceroli monopalmitostearas, natrii laurilsulfas, pro compresso obducto corresp. natrium 2.330 mg. - onkologikum, multi-kinase-hemmer - synthetika

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - dasatinibum - compresse rivestite con film - dasatinibum 100 mg, cellulosum microcristallinum, lactosum monohydricum 138 mg, carmellosum natricum conexum, hydroxypropylcellulosum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, talcum, glyceroli monopalmitostearas, natrii laurilsulfas, pro compresso obducto corresp. natrium 2.912 mg. - onkologikum, multi-kinase-hemmer - synthetika

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - dasatinibum - compresse rivestite con film - dasatinibum 140 mg, cellulosum microcristallinum, lactosum monohydricum 193.2 mg, carmellosum natricum conexum, hydroxypropylcellulosum, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, talcum, glyceroli monopalmitostearas, natrii laurilsulfas, pro compresso obducto corresp. natrium 4.077 mg. - onkologikum, multi-kinase-hemmer - synthetika

Eiropas Savienība - itāļu - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenti antineoplastici - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Eiropas Savienība - itāļu - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - agenti antineoplastici - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - dasatinibum - compresse rivestite con film - dasatinibum 20 mg ut dasatinibum monohydricum, lactosum monohydricum 26.261 mg, cellulosum microcristallinum, hydroxypropylcellulosum, carmellosum natricum conexum corresp. natrium max. 0.29 mg, magnesii stearas, Überzug: hypromellosum, triacetinum, e 171, pro compresso obducto. - philadelphiachromosom positivi cronica mieloide leucemia; philadelphiachromosom positivi per la leucemia linfatica acuta - synthetika